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Abstract
Purpose: Circulating Tumor Cells (CTCs) detection and phenotyping are currently evaluated in Breast Cancer (BC). Tumor
cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs
and HER2 expression on CTCs across the spectrum of BC staging.
Methods: Spiking experiments with 6 BC cell lines were performed and blood samples from healthy women and women
with BC were analyzed for HER2-positive CTCs using the CellSearchH.
Results: Based on BC cell lines experiments, HER2-positive CTCs were defined as CTCs with HER2 immunofluoresence
intensity that was at least 2.5 times higher than the background. No HER2-positive CTC was detected in 42 women without
BC (95% confidence interval (CI) 0–8.4%) whereas 4.1% (95%CI 1.4–11.4%) of 73 patients with ductal/lobular carcinoma in
situ (DCIS/LCIS) had 1 HER2-positive CTC/22.5 mL, 7.9%, (95%CI 4.1–14.9%) of 101 women with non metastatic (M0) BC had
$1 HER2-positive CTC/22.5 mL (median 1 cell, range 1–3 cells) and 35.9% (95%CI 22.7–51.9%) of 39 patients with metastatic
BC had $1 HER2-positive CTC/7.5 mL (median 1.5 cells, range 1–42 cells). In CTC-positive women with DCIS/LCIS or M0 BC,
HER2-positive CTCs were more commonly detected in HER2-positive (5 of 5 women) than HER2-negative BC (5 of 12
women) (p=0.03).
Conclusion: HER2-positive CTCs were detected in DCIS/LCIS or M0 BC irrespective of the primary tumor HER2 status.
Nevertheless, their presence was more common in women with HER2-positive disease. Monitoring of HER2 expression on
CTCs might be useful in trials with anti-HER2 therapies.
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Introduction
Minimal residual disease (MRD) after primary surgery is
thought to contribute to disease relapse in early breast cancer
(BC) [1;2]. The presence of peripheral blood Circulating Tumor
Cells (CTCs) is considered as a surrogate marker for the evaluation
of MRD. CTCs are epithelial tumor cells detected in the
peripheral blood of patients with solid tumors using mainly
cytometric/antibody-based and molecular approaches [1;2].
Currently, CellSearchH is the only technology for CTC detection
that has been cleared by the Food and Drug administration (FDA)
as an aid in the monitoring of patients with metastatic breast,
colorectal and prostate cancers. The detection of $5 CTCs/
7.5 mL of peripheral blood before starting a new treatment in
metastatic BC was associated with worse clinical outcome [3].
Data for CTC detection and phenotyping in early BC by
CellSearchH are only now emerging. In the German Success trial,
$1 CTC/23 mL of peripheral blood were detected in 20% and
21% of approximately 1500 patients with early BC before or after
adjuvant chemotherapy, respectively [Rack B, et al. 2010 J Clin
Oncol 28:7s; suppl; abstr 1003]. Two multicenter neoadjuvant
studies (Remagus II and GeparQuattro) and two single center
studies have used CellSearchH for CTC detection in early BC [4–
7]. In the Remagus II study, detection of $1 CTC/7.5 mL before,
after neoadjuvant chemotherapy or at both time points was
associated with worse distant metastasis free survival (DMFS) and
overall survival (OS) at a median follow-up of 36 months [8]. In
the GeparQuattro trial, HER2 overexpressing CTCs were
observed in 14 of 58 CTC-positive cases (24.1%) including 8
patients with HER2-negative primary tumors and 3 patients after
neoadjuvant trastuzumab. Several groups have reported the
detection of bone marrow HER2-positive DTCs or peripheral
blood HER2-positive CTCs in BC using different detection
methods [9–15].
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that cytokeratin positive (CK+) cells and HER2 expressing cells
(HER2+) became detectable in bone marrow at as early as 4–9
weeks of age when the most detailed analysis of the mammary
gland could only detect areas of atypical ductal hyperplasia (ADH)
[16]. The same investigators reported the detection of CK+ tumor
cells in the bone marrow of 13% of 39 women with DCIS [16].
Based on these findings, Husemann et al suggested that systemic
spread is an early step in BC progression [16].
To interrogate tumor cell dissemination during BC progression,
we sought to detect CTCs and study the expression of HER2 on
CTCs across the spectrum of BC staging: ductal/lobular
carcinoma in situ, (DCIS/LCIS), early invasive (M0) and
metastatic (M1) BC. To this aim, we used the CellSearchH
technology (Veridex, New Jersey, USA), a semi-automated system
for the detection and HER2 phenotypic profiling of CTCs. At the
same time, we developed a method to quantify HER2 expression
on CTCs.
Methods
Patients
Women with DCIS/LCIS, M0 and M1 BC treated at the
Institut Jules Bordet (IJB), Ho ˆpital Saint Pierre and Ho ˆpital
Universitaire Erasme in Belgium between November 2007 and
June 2009 were screened. Characteristics of the patients included
in this study are presented in Table 1. All patients received
locoregional and systemic treatment according to local institution-
al practice. The blood draw was performed in women with DCIS/
LCIS 3 weeks after primary surgery up to 5 years after primary
diagnosis, in women with M0 BC either before the initiation of
(neo) adjuvant chemotherapy or during the follow-up period up to
5 years from the initial diagnosis and in women with M1 BC either
before starting a new treatment for progressive disease or while
receiving treatment for stable or responding disease. Women with
a second BC were excluded from the analysis unless the two lesions
were diagnosed within a year or the two lesions had concordant
HER2 status. Every patient and healthy women included in this
study signed a written informed consent. This study was approved
by the Ethics Committee of the Institut Jules Bordet (reference
CE1468), the Ethics Committee of Centre Hospitalier Universi-
taire Saint Pierre (reference AK/08-04-3575/27) and the Ethics
Committee of Universite ´ Libre de Bruxelles (ULB)- Ho ˆpital
Erasme (reference P2007/303).
For healthy women, women with DCIS/LCIS and M0 BC
patients, HER2-positive CTCs were detected using a modified
ficoll procedure to reduce the 22.5 mL of peripheral blood draw to
7.5 mL that could then be processed on the CellSearchH. This step
was performed in order to increase the sensitivity of the technique
for earlier stages of the disease. For patients with M1 disease,
7.5 mL of blood were drawn from each patient to detect HER2-
positive CTCs using the CellSearchH. The first 5 mL of blood
obtained in this study was always discarded to avoid epithelial cell
contamination from the skin.
HER2-positive CTC detection using the CellSearchH
Peripheral blood samples were enriched for cells expressing the
epithelial-cell adhesion molecule (EPCAM) with antibody-coated
magnetic beads, and cells were labeled with the fluorescent nucleic
acid dye 4,2-diamidino-2-phenylindole dihydrochloride. Fluores-
cently labeled monoclonal antibodies specific for leukocytes
(CD45–allophycocyan) and epithelial cells (cytokeratin 8,18,19–
phycoerythrin) were used to distinguish epithelial cells from
leukocytes. Moreover, the CellSearchH Tumor Phenotyping
Reagent HER2 (a fluorescein conjugated monoclonal antibody)
was used in conjunction with the CellSearchH Epithelial Cell Kit
to phenotype CTCs for the presence of HER2. The identification
and enumeration of CTCs was performed using the CellSearchH
Analyzer, a semi-automated fluorescence-based microscopy sys-
tem that permits computer-generated reconstruction of cellular
images [17;18]. CTCs were defined as nucleated cells lacking
CD45 and expressing cytokeratin [17;18]. Quality control was
maintained via the CellSearchH CTC Control Kit used to
standardize reagents, instruments, and operator technique.
HER2 expression on CTCs using CellSearchH was calibrated
through peripheral blood spiking experiments with MCF7, ZR75-
1, BT20, MDA MB361, SKBR3 and BT474 cell lines. Briefly,
22.5 mL of peripheral blood from a healthy donor were spiked
with approximately 500 cells from these cell lines and then
processed by a modified ficoll procedure and the CellSearchH
using the same protocol described above for patients with localized
disease. The intensity of HER2 staining of CTCs from patients
with BC observed on the FITC channel of the CellSearchH system
was a continuous variable ranging from absent to very weak, weak,
intermediate, bright and very bright staining. Riethdorf et al [5]
proposed a model in which HER2 staining of CTC by
CellSearchH was classified as 0, 1+,2 +,3 +. We sought to develop
a method to quantify HER2 expression on CTCs. To that aim, we
assessed HER2 intensity on CTCs using a formula that calculates
how many times the HER2 staining intensity of the cell is higher
from background:
Table 1. Patient characteristics.
DCIS/LCIS
(N=73)
M0 Breast Cancer
(N=101)
M1 Breast Cancer
(N=39)
Age
#50 19 49 13
.50 52 52 26
Unknown 2
ER
Positive 50 84 34
Negative 15 17 5
Unknown 8
PR
Positive 46 66 26
Negative 19 35 13
Unknown 8
HER
Positive 19 19 6
Negative 33 81 33
Unknown 21 1
Histology Grade
19 1 02
21 2 4 92 0
34 2 3 61 3
Unknown 10 6 4
M0: Non-metastatic Breast Cancer, M1: Metastatic Breast Cancer, DCIS: Ductal
Carcinoma in situ, LCIS: Lobular Carcinoma in situ, ER: Estrogen receptor, PR:
Progesterone Receptor, HER2: Erbb2.
doi:10.1371/journal.pone.0015624.t001
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Foreground Intensity Cell HER2 staining ðÞ = Surface Area
Background Intensity = Surface Area
The Foreground Intensity (Cell HER2 staining)/Surface Area
and the Background Intensity/Surface Area have been calculated
using the ‘‘Aida Image Analyzer v3.45’’ software. The reproduc-
ibility of this method to quantify HER2 expression on CTCs was
assessed by 3 independent readers that quantified the HER2
Intensity CellSearchH of 30 CTCs.
Representative CellSearchH images of 15 cells from each cell
line were analyzed and the median HER2 Intensity for each cell
line was calculated. In addition, HER2 gene status for the above
cell lines was analyzed by fluorescence in situ hybridization (FISH),
(Pathvysion, Abbott-VysisH) (60 nuclei were analyzed per cell line).
HER2 protein expression was assessed by immunocytochemistry
(ICC) on slides spotted with 5000 cells from each cell line. HER2
Intensity CellSearchH was correlated with the results from FISH and
ICC for HER2.
Independent Blind Central Image Review by Veridex
For CellSearchH, source of variability between different labs has
been considered the inter-reader variability [19]. This becomes
more important in early BC where CTCs are present in very low
numbers [19]. Therefore, in order to assure the quality of our
results, an independent blind review of the entire set of CellSearchH
images from 86 cases of healthy women and women with BC was
performed by Pharma Testing Services, CellSearchH, Veridex US.
Only events that met stringent criteria for CTC definition by
CellSearchH were considered as positive. Results of the review were
discussed between IJB investigators and Veridex. A review of all
remaining cases was performed by IJB investigators using the same
stringent criteria for CTC definition by CellSearchH.
Primary tumor characteristics
The Elston-Ellis modification of the Scarff-Bloom-Richardson
(SBR) grading system (Nottingham grading system) was used to
define histological grade [20]. Estrogen and progesterone receptor
(ER and PR) were scored based on Harvey et al [21] and Leake
et al [22]. HER2 status of the primary tumor was determined
according to the American Society of Clinical Oncology/College
of American Pathologists Guideline Recommendations using
immunohistochemistry and FISH [23].
Statistical analysis
Associations between categorical variables were assessed using
the chi-square test. The Mann-Whitney test was used to compare
continuous variables between 2 groups. Pearson correlation was
used to assess correlation between continuous variables. Analyses
were performed using SPSS (SPSS Inc. Chicago, IL) version 15.0.
Results are reported according to the REMARK guidelines [24].
Results
CTCs in Breast Cancer
As a control group, we studied 36 healthy women and 6 women
operated for atypical ductal/lobular hyperplasia (ADH/ALH).
The detection rate in the control group was 3/42 or 7.1% (95%CI
2.5–19.0%, median 1 cell, range 1–2 cells). In 73 women with
DCIS/LCIS, $1 CTC/22.5 mL of blood was observed in 6/73
or 8.2% (95%CI 3.8–16.7%, median 1 cell, range 1–2 cells). In
101 women with M0 BC, we observed $1 CTC/22.5 mL in
11.9% (95%CI 5.7–18.3%, median 1 cell, range 1–4 cells). No
association was observed between patient characteristics and
detection of $1 CTC/22.5 mL in M0 breast cancer (Table 2).
Finally, among 39 women with metastatic BC, we detected $1
CTC/7.5 mL of blood in 23/39 or 59% (95%CI 43.4–72.9%,
median 9 cells, range 1–640 cells).
HER2 staining on CTCs
HER2 expression of 6 BC cell lines was evaluated using
CellSearchH and HER2 Intensity CellSearchH for each cell was
calculated as described in the methods. In the same cell lines,
HER2 gene status was assessed by FISH and HER2 protein
expression by ICC (Figure 1A, B, C). Median HER2 Intensity
CellSearchH in these cell lines correlated both with the results of the
FISH for HER2 gene (pearson correlation 0.92, p=0.03) and ICC
for HER2 protein (pearson correlation 0.89, p=0.04) (Table 3).
HER2 Intensity CellSearchH can be used as a continuous variable.
In order to assess the reproducibility of our method to quantify
HER2 expression on CTCs, 3 independent readers quantified the
HER2 Intensity CellSearchH of 30 CTCs (Table S1). We observed
more than 99% correlation in HER2 Intensity CellSearchH between
the independent readers (pearson correlation reader 1 vs 2: 0.99,
p,0.001, reader 1 vs 3: 1.00, p,0.001, reader 2 vs 3: 1.00,
p,0.001).
Depending on the biological and clinical research question,
different cut offs can be also used in order to define HER2-positive
CTCs. A higher cut off can define CTCs with HER2 protein over
expression/HER2 gene amplification in a more specific but less
sensitive way than a lower cut off. We fixed a cut off for HER2
Table 2. CTCs detection and patient characteristics in non
metastatic invasive (M0) breast cancer.
All patients $1 CTCs/22.5 mL
N N (%) P-value
Age
#50 49 6 (12) 0.91
.50 52 6 (11)
ER
Positive 84 8 (9) 0.10
Negative 17 4 (23)
PR
Positive 66 7 (11) 0.59
Negative 35 5 (14)
HER
Positive 19 4 (21) 0.18
Negative 81 8 (10)
Histology Grade
1 10 2 (20) 0.22
2 49 3 (6)
3 36 6 (17)
(Neo) adjuvant
Chemotherapy
Blood draw before 65 9 (14) 0.41
Blood draw after 36 3 (8)
ER: Estrogen receptor, PR: Progesterone Receptor, HER2: Erbb2.
doi:10.1371/journal.pone.0015624.t002
HER2-Positive CTCs in Breast Cancer
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background so that all MCF7, ZR75-1 and BT20 cells (cell lines
without HER2 amplification) were considered HER2-negative by
CellSearchH, whereas two third (67%) of MDA MB361 (cell line
with moderate HER2 amplification) and all SKBR3 and BT474
cells (cell lines with strong HER2 amplification) were considered
HER2-positive. Therefore, in the present study we considered a
CTC as HER2-positive by CellSearchH if there was a HER2
staining in the FITC channel compatible with a cell morphology
and a HER2 Intensity CellSearchH that was at least 2.5 times higher
than the background (Figure 2, Table S2).
HER2-positive CTCs in Breast Cancer
No HER2-positive CTC was observed in any of the 36 healthy
women or the 6 women operated for ADH/ALH (95%CI 0–
8.4%). Interestingly, 3 of 73 patients with DCIS/LCIS had 1
HER2-positive CTC/22.5 mL (4.1%, 95%CI 1.4–11.4%) and 8
of 101 patients with M0 BC had $1 HER2-positive CTC/
22.5 mL (7.9%, 95%CI 4.1–14.9%, median 1 cell, range 1–3
cells). Among women with DCIS/LCIS or M0 BC and detectable
CTCs, 5 of 5 women with HER2-positive tumors versus 5 out of
12 women with HER2-negative primary tumors had $1 HER2-
positive CTC (p=0.03).
Figure 1. HER2 protein expression and gene amplification in 6 breast cancer cell lines. After spiking experiments with these cell lines,
HER2 protein expression was evaluated using the CellSearchH technology (FITC-labeled anti-HER2 antibody) and intensity of HER2
immunofluorecence were evaluated using the HER2 Intensity CellSearchH formula as described in the methods. In the same cell lines, HER2
protein expression was assessed by ICC (B) and HER2 gene status by FISH (C).
doi:10.1371/journal.pone.0015624.g001
Table 3. HER2 Intensity CellSearchH (HER2 protein), Immunocytochemistry, ICC (HER2 protein), fluorescence in situ hybridization,
FISH (HER2 gene) in 6 breast cancer cell lines.
Cell Line
HER2 Intensity CellSearchH
(HER2 protein)
ICC
(HER2 protein)
FISH
(HER2 gene)
Median Range Scoring HER2/CEP17 FISH Ratio
MCF7 1.0 1.0–2.0 0 1.0
ZR75-1 1.0 1.0–1.8 1+ 1.2
BT20 1.0 1.0–2.2 1+ 1.8
MDA MB361 3.1 1.0–11.2 2+ 2.9
SKBR3 11.6 4.7–256.8 3+ 4.2
BT474 39.3 4.2–175.5 3+ 5.9
doi:10.1371/journal.pone.0015624.t003
HER2-Positive CTCs in Breast Cancer
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7.5 mL were detected in 14/39 or 35.9% (95%CI 22.7–51.9%,
median 1.5 cells, range 1–42 cells). Among 33 women with M1 BC
and HER2-negative primary tumor, $1 HER2-positive CTC/
7.5 mL were detected in 39.4%, (95%CI 24.7–56.3%, median 1.5
cells, range 1–42 cells).
Discussion
In the present study $1 CTC/22.5 mL of blood were detected
in 7.1% of women without BC, 8.2% of women with DCIS/LCIS
and 11.9% of women with M0 BC. Pierga et al. detected $1
CTC/7.5 mL in 23% of 97 patients before the administration of
neoadjuvant chemotherapy and in 17% of 86 patients after the
administration of neoadjuvant chemotherapy [4]. Riedthorf et al.
detected $1 CTC/7.5 mL in 21.6% of 213 patients before
neoadjuvant treatment (NT) and in 10.6% of 207 patients after
NT [5]. Sandri et al. detected one to three CTCs/30 mL in
approximately 30% of 56 patients with localized BC before
surgery [7]. Lang et al. detected $1 CTC/30 mL of blood in 38%
of 92 patients [6]. In the SUCCESS study, $1 CTC/23 mL of
peripheral blood were detected in 20% and 21% of patients before
or after adjuvant chemotherapy, respectively in a cohort of
approximately 1500 patients with early BC [Rack B, et al. 2010 J
Clin Oncol 28:7s; suppl; abstr 1003]. In the above studies, blood
draws were performed before primary surgery with the exception
of the SUCCESS study in which blood draws were performed 3
weeks after surgery and at the end of chemotherapy. The lower
CTC detection rates in M0 BC in our series could be due: (1) to
the fact that blood draw was not performed before primary
surgery but instead 3 weeks after surgery up to 5 years from the
diagnosis, (2) a step of ficoll enrichment was performed which is
known to lead to cell loss [25], (3) only cells meeting the stringent
criteria for CTC definition by CellSearchH were considered
positive after an independent blind review by Veridex. Although a
direct comparison between different studies cannot be performed,
the CTC detection rate when analyzing 22.5 mL of blood by
CellSearchH after a modified ficoll procedure in our study was not
higher than the CTC detection in 7.5 mL of blood by Pierga et al
[4] and Riedthorf et al [5]. Our results question the utility of
applying a modified ficoll procedure, before CellSearchH, which
may additionally increase complexity and raise issues of repro-
ducibility among laboratories.
We have developed the HER2 Intensity CellSearchH formula which
allows for the quantification of HER2 immunofluoresence
intensity by CellSearchH. By performing spiking experiments
using 6 BC cell lines, we propose that HER2-positive CTCs can be
considered as those having HER2 Intensity CellSearchH that is at least
2.5 higher than the background. The clinical utility of defining
HER2-positive CTCs based on the above cut off should be
prospectively tested. In this study, we have detected no HER2-
positive CTC in 42 women without BC, $1 HER2-positive CTC/
22.5 mL in 4.1% of women with DCIS/LCIS and 7.9% of
women with M0 BC. The detection of HER2-positive CTCs in
women with DCIS/LCIS is in line with the early dissemination
model of BC metastasis suggested by Husemann et al [16]. Further
studies are needed to validate these results. We have reported the
detection of HER2-positive CTCs in women with HER2-negative
early BC as other investigators using CellSearchH or different
technologies [5;9–11]. In our series of non metastatic BC, HER2-
positive CTCs were more commonly detected in HER2-positive as
opposed to HER2-negative primary tumors but these results
should be interpreted with caution due to the low number of cases
with HER2-positive CTCs. Furthermore, as reported by other
investigators [12–15] we have detected HER2-positive CTCs in
women with metastatic BC and initially HER2-negative primary
tumors.
The role of CTCs or HER2-positive CTCs in metastatic BC is
currently evaluated in clinical trials. Example of such a trial is the
Southwest Oncology Group (SWOG) trial (ClinicalTrials.gov
NCT00382018) which is testing the strategy of changing
chemotherapy compared with continuing the same treatment for
metastatic BC patients with elevated CTCs levels at the first
follow-up assessment. Another example is the study of lapatinib in
advanced BC patients with HER2 non-amplified primary tumors
and HER2 positive or EGFR positive CTCs (ClinicalTrials.gov
NCT00820924). The clinical utility of CTCs or HER2-positive
CTCs in early BC for patient stratification and as biomarkers to
Figure 2. CellSearchH images of CTCs from patients with breast cancer. HER2-positive CTCs were considered as CTCs having HER2 Intensity
CellSearchH $2.5.
doi:10.1371/journal.pone.0015624.g002
HER2-Positive CTCs in Breast Cancer
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with agents like biphosphonates or anti HER2 agents should be
prospectively tested.
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